Dissecting the tumour immune microenvironment in merkel cell carcinoma based on a machine learning framework
Volume 51, Issue 1, December 2023, Page 397-407 . (Source: Artificial Cells, Blood Substitutes, and Biotechnology)
Source: Artificial Cells, Blood Substitutes, and Biotechnology - September 7, 2023 Category: Biotechnology Authors: Shaowen Cheng Si Li Ping Yang Rong Wang Ping Zhou Jingquan Li Source Type: research
Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes
CONCLUSIONS: Among patients with primary MCC who had RT as a component of their initial treatment strategy, anatomically-driven heterogeneous treatment approaches were associated with equally excellent locoregional disease control.PMID:37659660 | DOI:10.1016/j.radonc.2023.109892 (Source: Cancer Control)
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Samuel Cass Brandon Cope Andrew J Bishop Yi-Ju Chiang B Ashleigh Guadagnolo Ahsan Farooqi William Morrison Russell G Witt Riyad N H Seervai Adam S Garden Clifton D Fuller Ryan P Goepfert Merrick Ross Jeffrey E Gershenwald Michael Wong Phyu P Aung Emily Z Source Type: research
Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes
CONCLUSIONS: Among patients with primary MCC who had RT as a component of their initial treatment strategy, anatomically-driven heterogeneous treatment approaches were associated with equally excellent locoregional disease control.PMID:37659660 | DOI:10.1016/j.radonc.2023.109892 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 2, 2023 Category: Radiology Authors: Samuel Cass Brandon Cope Andrew J Bishop Yi-Ju Chiang B Ashleigh Guadagnolo Ahsan Farooqi William Morrison Russell G Witt Riyad N H Seervai Adam S Garden Clifton D Fuller Ryan P Goepfert Merrick Ross Jeffrey E Gershenwald Michael Wong Phyu P Aung Emily Z Source Type: research
Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes
CONCLUSIONS: Among patients with primary MCC who had RT as a component of their initial treatment strategy, anatomically-driven heterogeneous treatment approaches were associated with equally excellent locoregional disease control.PMID:37659660 | DOI:10.1016/j.radonc.2023.109892 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 2, 2023 Category: Radiology Authors: Samuel Cass Brandon Cope Andrew J Bishop Yi-Ju Chiang B Ashleigh Guadagnolo Ahsan Farooqi William Morrison Russell G Witt Riyad N H Seervai Adam S Garden Clifton D Fuller Ryan P Goepfert Merrick Ross Jeffrey E Gershenwald Michael Wong Phyu P Aung Emily Z Source Type: research
Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes
Merkel cell carcinoma (MCC) is a rare, cutaneous, neuroendocrine malignancy with rising incidence.1 MCC often presents as a rapidly growing, cutaneous or subcutaneous nodule on the head and neck (HN) or sun-exposed non-HN (NHN) areas.2 Beyond UV exposure, risk factors include older age, being immunocompromised, polyomavirus infection, and previous history of cutaneous malignancy.3 –5 The majority of MCC patients are diagnosed with locally-confined disease.5 Such stage I-II patients are often treated surgically with wide local excision (WLE) and sentinel lymph node biopsy (SLNB). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - August 31, 2023 Category: Radiology Authors: Samuel Cass, Brandon Cope, Andrew J. Bishop, Yi-Ju Chiang, B. Ashleigh Guadagnolo, Ahsan Farooqi, William Morrison, Russell G. Witt, Riyad N.H. Seervai, Adam S. Garden, Clifton D. Fuller, Ryan P. Goepfert, Merrick Ross, Jeffrey E. Gershenwald, Michael Won Tags: Original Article Source Type: research
Surveillance and Deregulated Pathways in Oral Merkel Cell Carcinoma
Sir — Merkel cell carcinoma (MCC) is an infrequent and incredibly destructive cutaneous neuroendocrine tumour. The tumour cells include neurosecretory granules, which are similar to those found in healthy Merkel cells [1]. MCC commonly manifests as an erythematous lesion in the dermal region of skin t hat is expanding quickly [2]. Rapid systemic tumour progression is also present, together with rapid local growth. The liver, bone and brain are distant organs where MCC frequently metastasises [3]. (Source: Clinical Oncology)
Source: Clinical Oncology - August 31, 2023 Category: Radiology Authors: D.J. Mukesh Kumar, P. Ramasamy, S. Suresh Kumar, P. Sivagurunathan Tags: Letter Source Type: research
Characterization of molecular mechanisms driving Merkel cell polyomavirus oncogene transcription and tumorigenic potential
In this study, we investigated how MCPyV early transcription is regulated to support viral infection and MCC tumorigenesis. Our studies established the roles of multiple cellular factors in the control of MCPyV gene expression. Inhibitor screening experiments revealed that the histone acetyltransferases p300 and CBP positively regulate MCPyV transcription. Their regulation of viral gene expression occurs through coactivation of the transcription factor NF-κB, which binds to the viral genome to drive MCPyV oncogene expression in a manner that is tightly controlled through a negative feedback loop. Furthermore, we discovere...
Source: Cancer Control - August 30, 2023 Category: Cancer & Oncology Authors: June F Yang Wei Liu Jianxin You Source Type: research
LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition
ConclusionsThese findings strongly suggest that in pre-clinical studies, DNA vaccination with ITI-3000, using the UNITE™ platform, enhances CD4 T cell responses to MCPyV-LT that result in significant anti-tumor immune responses. These data support the initiation of a first-in-human (FIH) Phase 1 open-label study to evaluate the safety, tolerability, and immunogenicity of ITI-3000 in patients with polyomavirus-positive MCC (NCT05422781). (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - August 30, 2023 Category: Allergy & Immunology Source Type: research
The emerging role of miRNAs in Merkel cell carcinoma pathogenesis: Signaling pathway crosstalk
Pathol Res Pract. 2023 Aug 19;249:154771. doi: 10.1016/j.prp.2023.154771. Online ahead of print.ABSTRACTMerkel cell carcinoma (MCC) is an uncommon invasive form of skin cancer that typically manifests as a nodule on the face, head, or neck that is flesh-colored or bluish-red in appearance. Rapid growth and metastasis are hallmarks of MCC. MCC has the second-greatest mortality rate among skin cancers after melanoma. Despite the recent cascade of molecular investigations, no universal molecular signature has been identified as responsible for MCC's pathogenesis. The microRNAs (miRNAs) play a critical role in the post-transcr...
Source: Pathology, Research and Practice - August 23, 2023 Category: Pathology Authors: Nehal I Rizk Heba M Midan Gouda Kamel Helal Ahmed I Abulsoud Shereen Saeid Elshaer Ahmed A El-Husseiny Doaa Fathi Nourhan M Abdelmaksoud Sherif S Abdel Mageed Mohammed S Elballal Mohamed Bakr Zaki Mai A Abd-Elmawla Tohada M Al-Noshokaty Mahmoud A Elrebehy Source Type: research
The emerging role of miRNAs in Merkel cell carcinoma pathogenesis: Signaling pathway crosstalk
Pathol Res Pract. 2023 Aug 19;249:154771. doi: 10.1016/j.prp.2023.154771. Online ahead of print.ABSTRACTMerkel cell carcinoma (MCC) is an uncommon invasive form of skin cancer that typically manifests as a nodule on the face, head, or neck that is flesh-colored or bluish-red in appearance. Rapid growth and metastasis are hallmarks of MCC. MCC has the second-greatest mortality rate among skin cancers after melanoma. Despite the recent cascade of molecular investigations, no universal molecular signature has been identified as responsible for MCC's pathogenesis. The microRNAs (miRNAs) play a critical role in the post-transcr...
Source: Pathology, Research and Practice - August 23, 2023 Category: Pathology Authors: Nehal I Rizk Heba M Midan Gouda Kamel Helal Ahmed I Abulsoud Shereen Saeid Elshaer Ahmed A El-Husseiny Doaa Fathi Nourhan M Abdelmaksoud Sherif S Abdel Mageed Mohammed S Elballal Mohamed Bakr Zaki Mai A Abd-Elmawla Tohada M Al-Noshokaty Mahmoud A Elrebehy Source Type: research
The emerging role of miRNAs in Merkel cell carcinoma pathogenesis: Signaling pathway crosstalk
Pathol Res Pract. 2023 Aug 19;249:154771. doi: 10.1016/j.prp.2023.154771. Online ahead of print.ABSTRACTMerkel cell carcinoma (MCC) is an uncommon invasive form of skin cancer that typically manifests as a nodule on the face, head, or neck that is flesh-colored or bluish-red in appearance. Rapid growth and metastasis are hallmarks of MCC. MCC has the second-greatest mortality rate among skin cancers after melanoma. Despite the recent cascade of molecular investigations, no universal molecular signature has been identified as responsible for MCC's pathogenesis. The microRNAs (miRNAs) play a critical role in the post-transcr...
Source: Pathology, Research and Practice - August 23, 2023 Category: Pathology Authors: Nehal I Rizk Heba M Midan Gouda Kamel Helal Ahmed I Abulsoud Shereen Saeid Elshaer Ahmed A El-Husseiny Doaa Fathi Nourhan M Abdelmaksoud Sherif S Abdel Mageed Mohammed S Elballal Mohamed Bakr Zaki Mai A Abd-Elmawla Tohada M Al-Noshokaty Mahmoud A Elrebehy Source Type: research
Cancers, Vol. 15, Pages 4201: Lymph Node Metastases from Non-Melanoma Skin Cancer of the Head and Neck
P. Takes
Alfio Ferlito
Non-melanoma skin cancer (NMSC) represents the most common malignancy in the world, comprising exceedingly common lesions such as basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) and rare lesions such as Merkel cell carcinoma. Risk factors are widely recognized and include ultraviolet (UV) light exposure, radiation exposure, immunosuppression, and many others. As a whole, survival and functional outcomes are favorable, but each histopathological subtype of NMSC behaves differently. Treatment regimens for the primary site usually include wide surgical excision and neck dis...
Source: Cancers - August 22, 2023 Category: Cancer & Oncology Authors: Francisco Civantos Zachary M. Helmen Patrick J. Bradley Andr és Coca-Pelaz Remco De Bree Orlando Guntinas-Lichius Luiz P. Kowalski Fernando L ópez Antti A. M äkitie Alessandra Rinaldo K. Thomas Robbins Juan P. Rodrigo Robert P. Takes Alfio Ferlito Tags: Review Source Type: research
LB1691 The relationship of age and body mass index with immunotherapy response in merkel cell carcinoma: Analysis of 183 patients
Merkel cell carcinoma (MCC) is an aggressive skin cancer with a high risk of metastasis. Development of anti-PD-1/PD-L1 immunotherapy (IMTX) has significantly improved outcomes for advanced MCC. Currently, ∼50% of patients have durable benefit from IMTX. It is important to identify factors that influence IMTX response. Studies of several cancer types (melanoma, renal cell, and non-small-cell lung cancer) have demonstrated an association between older age or higher BMI with improved IMTX response and overall survival (OS). (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - August 21, 2023 Category: Dermatology Authors: R. Alam, X. Fan, D.S. Hippe, E.T. Huynh, E. Gong, S. Park, P. Nghiem Source Type: research
LB1690 Definitive radiotherapy for initial management of merkel cell carcinoma: Assessing a novel hypo-fractionated regimen
Merkel cell carcinoma (MCC) is a rare skin cancer. Standard therapy often includes surgery and post-operative radiation (PORT). Given the radiosensitivity of MCC, definitive radiotherapy (RT) may be effective when surgery is contraindicated due to morbidity, functional compromise, and/or delayed wound healing. Here we retrospectively analyzed the efficacy of definitive RT for patients (pts) who received hypo-fractionated RT (hRT; 8 Gy x 1-3 fractions) versus conventional RT (cRT; 1.8-2 Gy x 25-35 fractions). (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - August 21, 2023 Category: Dermatology Authors: A. Menon, E.T. Huynh, P.H. Goff, K. Lachance, M.H. Nguyen, J. Iyer, K. Nagase, K. Parvathaneni, P. Nghiem, U. Parvathaneni Source Type: research
